Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.55 |
| ▸ | HTR3B | O95264 | 2/20 | 0.55 |
| ▸ | HTR3A | P46098 | 2/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.55 |
| ▸ | PNMT | P11086 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.45 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.45 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.45 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27784793 | 0.94 | TAAR1 (0.57) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7741638 | 0.92 | TAAR1 (0.55) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7098955 | 0.92 | TAAR1 (0.55) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6527706 | 0.92 | TAAR1 (0.55) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL177421 | 0.87 | TAAR1 (0.63) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29566831 | 0.87 | TAAR1 (0.63) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5241228 | 0.87 | TAAR1 (0.68) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31567921 | 0.85 | TAAR1 (0.65) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4402199 | 0.84 | TDP1 (0.46) | TAAR1 | |
| SCHEMBL12050856 | 0.82 | TAAR1 (0.74) | TAAR1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145659-A1 | HETEROCYCLE FUSED GAMMA-CARBOLINES ACTING ON THE SEROTONINE 5-HT2A RECEPTOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-0414686-A1 | DERIVATIVES OF TRIFLUOROMETHYL-1-TETRALINES, PREPARATION AND APPLICATION THEREOF FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES. | LUCIEN LAB (FR) | 1991-03-06 | — | — | EP | disclosed |
| EP-0383950-A1 | PYRIDINE DERIVATIVES AND INSECTICIDAL AND MITICIDAL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-08-29 | — | — | EP | disclosed |
| WO-1989004819-A1 | DERIVATIVES OF TRIFLUOROMETHYL-1-TETRALINES, PREPARATION AND APPLICATION THEREOF FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES | LABORATOIRES LUCIEN (FR) | 1989-06-01 | — | — | WO | disclosed |
| US-4689341-A | Antiarrhythmic imidazoles | SCHERING A.G. (DE) | 1987-08-25 | — | — | US | disclosed |
| US-4613609-A | Antiarrhythmic imidazoliums | SCHERING A. G. (DE) | 1986-09-23 | — | — | US | disclosed |
| US-4581370-A | Antiarrhythmic imidazoliums | SCHERING A.G. (DE) | 1986-04-08 | — | — | US | disclosed |
| EP-0131302-A2 | Imidazolium salts, intermediates thereto and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-01-16 | — | — | EP | disclosed |
| EP-0064244-A1 | Spermicidal 1-bis(arylalkyl)alkylimidazoles | SYNTEX (U.S.A.) INC. (US) | 1982-11-10 | — | — | EP | disclosed |
| US-4210610-A | CHLOROARYLHYDROXY SUBSTITUTED ACETYLENES | GULF RESEARCH AND DEVELOPMENT COMPANY (US) | 1980-07-01 | — | — | US | disclosed |
| EP-0004447-A2 | Preparation of trifluoromethylphenols and novel trifluoromethylphenyl benzyl ether intermediates | ELI LILLY AND COMPANY (US) | 1979-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | TAAR1 197/4885HTR3E 1173/4885HTR3B 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.